IND for GI-108 in Phase 1/2a, approved by the MFDS in South Korea

GI-102 and GI-128, Securing Korea Drug Development Fund’s Clinical and Leading Substances Project

IND of GI-102 amendment approved with phase 1/2 by FDA

GI-102, singed with MSD for New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 in Combination with KEYTRUDA® (pembrolizumab)

Registration of a substance patent for GI-101A/102 in China

Advanced or metastatic sarcoma of GI-102, designated as Orphan Drug from FDA

IND of GI-102 amendment approved with phase 1/2 by FDA

Registration of substance patent for GI-101A/102 in Europe

GI-301, allergy treatment received out-licensing prize of Korea New Drug Award

Signing in MOU with SLvaxigen for clinical trial for metastatic prostate cancer

Implementation of bonus issue

Received 'the innovative pharmaceutical company' prize from the minister of Health and Welfare in Korea

Registering patent of combination therapies for GI-101 and GI-102, with blockbuster anti-cancer drugs in U.S.

Out-licensing agreement for GI-301 with Maruho worth up to 221M USD (exclusive in Japan)

Signing MOU for co-development of 4th generation metabolic immune anti-cancer drug with Future Medicine

US FDA approved modification of IND in phase 1/2 for GI-101

GI Innovation, listed in KOSDAQ

IND of GI-102 in phase 1/2, approved by MFDS South Korea

Selected as the innovative pharmaceutical firm

IND of GI-102, approved with phase 1/2a by FDA

Submitting Securities Registration Form

Approval for preliminary review to be listed in KOSDAQ

Patent registration of GI-101 in U.S.

Patent registration of GI-305 in domestic

Patent registration of GI-105 in domestic

merkel cell carcinoma of GI-101, designated as Orphan Drug from FDA

GI-108, matabolic immuno-oncology, securing $1.4M for pre-clinical project from Korea Drug Development Fund

Patent registration of GI-301 in Japan

Patent registration of GI-101 in Japan

Securing Korea Drug Development Fund’s clinical project worth for a maximum of $5.8M

Patent registration of GI-101 (Combination with Immune Checkpoint Inhibitor) in domestic

Submitting a preliminary application for KOSDAQ listing

Recruits Chief Executive Officer Byung-Geon Rhee Former CEO of GC Pharma, SCM Lifescience Corp.

GI Innovation·GI Cell·Yonsei University Health System, Signed MoU to establish a cell therapy center for advanced biopharmaceutical

Patent registration of GI-101 (Combination with Radiotheraphy) in domestic

Patent registration of GI-301 (Combination with Probiotics) in Japan

MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology

Patent registration of GI-101 in Taiwan

Patent registration of GI-210B1 in domestic

Korea excellent patent grand prize

Patent registration of GI-311 in Israel, Republic of south Africa

Certificate of IP Management Enterprise (Korean Intellectual Property Office)

Clinical collaboration with AstraZeneca
to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy

Patent registration of GI-301 in Republic of South Africa

Evaluate passage for the listing Unicorn track

MOU with Merck for a new biopharrmaceutical development

Patent registration of GI-104 in domestic

MOU with MediRama, a clinical development company, for new immune-oncology development

Patent registration of GI-311 in Taiwan

GI-301 MFDS South Korea phase 1 IND approved

The Certification of Excellent Company for Employee’s Invention Compensation

160 billion won worth of pre-IPO attract investment

GI-101 U.S. FDA phase 1/2 IND approved

GI-101 MFDS South Korea phase 1/2 IND approved

International Standard Information Protection ISO27001 Certification

Patent registration of GI-101 in domestic

MOU with Lunit for joint research for the next generation innovative new drug development

Patent registration of GI-301 in Taiwan

GI-101, Top 100 National R&D performances in 2020

MOU with Agilent for biomarker profiling collaboration in phase 1/2 study of GI-101

Out-licensing agreement for GI-301 with Yuhan

Clinical Collaboration Agreement with MSD to evaluate GI-101 in combination with Keytruda®

Licensing -in Agreement of immuno-oncology candidate substance from Ybiologics

COVID-19 vaccine immune booster cooperation development MOU with International Vaccine Institute

KRW 30.9 billion Series C financing & CDMO contract with DM BIO

Out-licensing agreement for GI-101 with Simcere

Patent in-licensing of GI-301 and GI-311 from Progen

MOU for co-development with Yuhan

KRW 37.5 billion in Series B financing

Received The Ministry of Health and Welfare Grant for GI-101 R&D

Strategic partnership for CLD and Manufacturing with Samsung Biologics

KRW 22.8 billion Series A financing

Strategic Development Partnership with Binex

Awardee of 'Global Challenger' in Korea Bio pharmaceuticals (GI-301)

MOU with Mediogen

Strategic Development Partnership with Samsung Biologics

Registration of our affiliate R&D center

Accreditation as a bio-venture by Korean Venture Capital Association

In-licensing Agreements for GI-301, GI-210 made with Progen

Foundation of GI Innovation